12 June 2019 01:30pm - 02:30pm Australia/Sydney
This session will discuss the importance of genomic data in understanding blood group antigen profiles for Indigenous Australians and how this may guide transfusion practice.
|Presenter:||Maree Perry, Research assistant, Australian Red Cross Blood Service.|
17 April 2019 01:30pm - 02:30pm Australia/Sydney
This session will provide an update for the study 'Haemolytic disease of the fetus and newborn (HDFN) associated with blood groups: Digital PCR for this "atypical” panel for blood group typing'. The study recruits isoimmunised mothers from around Australia to assess the reliability and clinical utility of these 'in-house' non-invasive prenatal tests.
|Presenter:||Helen O'Brien, Senior Research Assistant, Australian Red Cross Blood Service.|
9 May 2018 Topic will be prerecorded and made available at 1:30PM EST
In good news for Australian Defence Force personnel, and potentially many civilian patients in the future, after five years of intense research and development, results for the Blood Service's Frozen Blood Project are heating up. This exciting work extends the shelf-life of blood components up to 10 years by adapting and developing blood freezing technologies, cryopreservation. Advances it this area are presented.
|Presenter:||Dr Lacey Johnson, Principal Research Fellow, Australian Red Cross Blood Service.|
20 September 2017 01:30pm - 02:00pm Australia/Sydney
This session will include an overview of the challenges faced by a transfusion laboratory as they perform pre-transfusion testing to find compatible blood for multiple myeloma patients undergoing Daratumumab therapy and how these issues can be resolved.
Ms Kerman Buhariwala is a Medical Scientist in Clinical Services and Research at the Blood Service.
23 August 2017 01:30pm - 02:00pm - Australia/Sydney
This session provides an overview of the testing provided as part of the pretransfusion testing process.
Ms Helen Stathopoulos is a Senior Transfusion Scientist at the Blood Service.
Transfusion Update Conference 2017: Day 2 - Friday 28 April 2017
Presenter: Dr Richard Kaufman, Associate Professor of Pathology, Harvard Medical School and Medical Director of Adult Transfusion Medicine Service, Brigham and Women's Hospital, United States of America.
4 March 2020 02.00pm - 03.00pm Australia/Sydney
A number of disorders, such as sickle cell anaemia, are triggered by defective adult haemoglobin. Sickle cell anaemia and beta thalassemia are the most common single-gene genetic disorders in the world, affecting millions of people, with enormous costs to health systems. Research has solved the 50-year-old mystery about how these mutations - which are naturally carried by a small percentage of people - operate and alter the expression of human genes.
Discovering the mutation responsible means that CRISPR gene editing whereby natural mutations are introduced. These can be used to turn on beneficial genes or repress harmful genes and, for example, boost red cell production of fetal haemoglobin.
With this discovery, there is potentially a way to fast-track the development of new therapies for sickle cell disease and other inherited conditions using CRISPR-Cas9 gene editing.
|Presenter:||Prof Merlin Crossley, Staff Specialist Haematologist Pathology North, John Hunter Children's Hospital, Calvary Mater Newcastle.|